Fosun Pharma gets nod for for H-share issue
Shanghai Fosun Pharmaceutical Group has received the go-ahead from the China Securities Regulatory Commission to issue new H-shares, which could raise HK$2.13bn ($274.30m) based on its current share price.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts